全文获取类型
收费全文 | 1100161篇 |
免费 | 75239篇 |
国内免费 | 1798篇 |
专业分类
耳鼻咽喉 | 15604篇 |
儿科学 | 35023篇 |
妇产科学 | 29216篇 |
基础医学 | 157249篇 |
口腔科学 | 29983篇 |
临床医学 | 97087篇 |
内科学 | 209731篇 |
皮肤病学 | 25289篇 |
神经病学 | 83271篇 |
特种医学 | 44345篇 |
外国民族医学 | 201篇 |
外科学 | 166705篇 |
综合类 | 22073篇 |
现状与发展 | 1篇 |
一般理论 | 277篇 |
预防医学 | 75678篇 |
眼科学 | 25362篇 |
药学 | 88461篇 |
7篇 | |
中国医学 | 3126篇 |
肿瘤学 | 68509篇 |
出版年
2021年 | 8479篇 |
2019年 | 8502篇 |
2018年 | 12160篇 |
2017年 | 9547篇 |
2016年 | 10957篇 |
2015年 | 12441篇 |
2014年 | 16633篇 |
2013年 | 23757篇 |
2012年 | 32810篇 |
2011年 | 34590篇 |
2010年 | 20362篇 |
2009年 | 19008篇 |
2008年 | 31630篇 |
2007年 | 33613篇 |
2006年 | 34083篇 |
2005年 | 32356篇 |
2004年 | 30819篇 |
2003年 | 29594篇 |
2002年 | 28492篇 |
2001年 | 60513篇 |
2000年 | 61924篇 |
1999年 | 51342篇 |
1998年 | 12638篇 |
1997年 | 11172篇 |
1996年 | 11149篇 |
1995年 | 10446篇 |
1994年 | 9447篇 |
1993年 | 8935篇 |
1992年 | 37986篇 |
1991年 | 36428篇 |
1990年 | 35891篇 |
1989年 | 34433篇 |
1988年 | 31018篇 |
1987年 | 30089篇 |
1986年 | 28325篇 |
1985年 | 26559篇 |
1984年 | 19284篇 |
1983年 | 16193篇 |
1982年 | 8871篇 |
1979年 | 17103篇 |
1978年 | 11458篇 |
1977年 | 10275篇 |
1976年 | 8866篇 |
1975年 | 10111篇 |
1974年 | 11690篇 |
1973年 | 11305篇 |
1972年 | 10786篇 |
1971年 | 10121篇 |
1970年 | 9280篇 |
1969年 | 8955篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
5.
6.
7.
8.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
9.
10.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献